Back to Search Start Over

Neurologic manifestations associated with COVID-19: a multicentre registry

Authors :
Elodie Meppiel
Nathan Peiffer-Smadja
Alexandra Maury
Imen Bekri
Cécile Delorme
Virginie Desestret
Lucas Gorza
Geoffroy Hautecloque-Raysz
Sophie Landre
Annie Lannuzel
Solène Moulin
Peggy Perrin
Paul Petitgas
François SellaI
Adrien Wang
Pierre Tattevin
Thomas de Broucker
Sophie Abgrall
Fanny Alby-Laurent
Thibault Allou
Joséphine Amevigbe
Hanifa Amarguellay
Nabil Alloussi
Guillaume Baille
Mathilde Barbaz
Lamia Bencherif
Samia Bensaadi
Guillaume Beraud
Alexandra Bizot
Laure Bottin
Fabrice Bruneel
Jean-Philippe Camdessanche
Jeanne Chauffier
Jean-Philippe Csajaghy
Chloé De Broucker
Thomas De Broucker
Luc Defebvre
Elodie Dembloque
Nathalie Derache
Olivier Dereeper
Céline Derollez
Cécile Descotes-Genon
Mathilde Devaux
Lydie Dubuc
Gilles Edan
Andréa Fickl
Thibault Fraisse
Michel Gugenheim
Karolina Hankiewicz
Yves Hansmann
Carole Henry
Stéphanie Jobard
Fanny Jouan
Arnaud Kwiatkowski
Thibault Lalu
Johan Leguilloux
Camille Lejeune
Clémence Liegeois
Sophie Mahy
Jonathan Marey
Laure Michel
Rita Mitri
Chloé Moulin
Asma Omarjee
Canan Ozsancak
Fernando Pico
Marie Poupard
Valérie Rabier
Camille Rizzato
Caroline Roos
Julien Saison
Naomi Sayre
Nicolas Sedillot
François Sellal
Jérôme Servan
Caroline Storey
Laurent Suchet
Paul Tarteret
Mathilde Thiebaut
Claudia Vaduva
David Varlan
Virginie Zarrouk
Centre Hospitalier de Saint-Denis [Ile-de-France]
Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord
Centre Hospitalier de Versailles André Mignot (CHV)
CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Hospices Civils de Lyon (HCL)
Hôpital Foch [Suresnes]
Hôpitaux Civils de Colmar
Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane)
CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG)
Centre Hospitalier Universitaire de Reims (CHU Reims)
Les Hôpitaux Universitaires de Strasbourg (HUS)
CHU Pontchaillou [Rennes]
Service de Neurologie [Hôpitaux Civils de Colmar]
Hôpitaux Civils Colmar
Jonchère, Laurent
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
Source :
Clinical Microbiology and Infection, Clinical Microbiology and Infection, Elsevier for the European Society of Clinical Microbiology and Infectious Diseases, 2020, ⟨10.1016/j.cmi.2020.11.005⟩, Clinical Microbiology and Infection, 2020, ⟨10.1016/j.cmi.2020.11.005⟩
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

International audience; OBJECTIVES: To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We conducted a single-centre retrospective study during the French coronavirus disease 2019 (COVID-19) epidemic in March-April 2020. All COVID-19 patients with de novo neurologic manifestations were eligible. RESULTS: We included 222 COVID-19 patients with neurologic manifestations from 46 centres in France. Median (interquartile range, IQR) age was 65 (53-72) years and 136 patients (61.3%) were male. COVID-19 was severe or critical in 102 patients (45.2%). The most common neurologic diseases were COVID-19-associated encephalopathy (67/222, 30.2%), acute ischaemic cerebrovascular syndrome (57/222, 25.7%), encephalitis (21/222, 9.5%) and Guillain-Barré syndrome (15/222, 6.8%). Neurologic manifestations appeared after the first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19-associated encephalopathy, 7 (5-10) days in encephalitis, 12 (7-18) days in acute ischaemic cerebrovascular syndrome and 18 (15-28) days in Guillain-Barré syndrome. Brain imaging was performed in 192 patients (86.5%), including 157 magnetic resonance imaging (70.7%). Among patients with acute ischaemic cerebrovascular syndrome, 13 (22.8%) of 57 had multiterritory ischaemic strokes, with large vessel thrombosis in 16 (28.1%) of 57. Brain magnetic resonance imaging of encephalitis patients showed heterogeneous acute nonvascular lesions in 14 (66.7%) of 21. Cerebrospinal fluid of 97 patients (43.7%) was analysed, with pleocytosis found in 18 patients (18.6%) and a positive SARS-CoV-2 PCR result in two patients with encephalitis. The median (IQR) follow-up was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). CONCLUSIONS: Clinical spectrum and outcomes of neurologic manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes.

Details

ISSN :
1198743X and 14690691
Volume :
27
Database :
OpenAIRE
Journal :
Clinical Microbiology and Infection
Accession number :
edsair.doi.dedup.....755a79dc94a42ef2a920c4b9fc507544